Uniphar appoints new global head of Scientific Communications
January 17, 2025UniPhar, appointment
Global partner to pharma, medtech and biotech companies Uniphar has announced the appointment of industry leader Isaac Batley as its …
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
January 17, 2025CPhI, Pharmpack, biologics, predictions
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025 13 …
David Loose appointed CEO of Essex Management
January 17, 2025David Loose has been appointed as chief executive officer of Essex Management, part of contract research organisation Emmes Group. After …
Dr Joerg Moeller appointed CEO of Antag Therapeutics
January 14, 2025Corporate
Novel obesity treatment-focused biopharmaceutical company Antag Therapeutics has announced the appointment of Joerg Moeller MD PhD as chief executive officer. …
Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report
January 14, 2025Switzerland, pharmapack, report
 Pharmapack Europe: ‘Basel the best location for drug device innovation in Europe thanks to combination of world class manufacturing and …
University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients
January 14, 2025Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients
The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …
AnaCardio raises $19m in funding round for heart failure candidate
January 10, 2025Research and Development AnaCardio, Cardiology, cardiology, funding, heart failure
Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for …
IDDI announces two new appointments to its leadership team
January 9, 2025IDDI, appointment, leadership
The International Drug Development Institute (IDDI) has announced changes to its executive leadership team to strengthen the company’s leadership and …
University of Southern Denmark pairs with Argobio to launch next-generation RNA company Inverna Therapeutics
January 7, 2025Research and Development Argobio, Huntingdon's Disease, Inverna therapeutics, Neurology, RNA therapeutics, University of Southern Denmark ], gene splicing
The launch of new RNA company Inverna Therapeutics was announced today. Inerva Therapeutics begins with a programme aimed at transforming …
NMD Pharma’s Charcot-Marie-Tooth disease treatment granted ODD by FDA
January 6, 2025CMT, FDA, NMD Pharma, Orphan Drugs, Pain, nervous system, research and development
Biotech company NMD Pharma has announced that the US Food and Drug Association (FDA) have granted its Charcot-Marie-Tooth (CMT) disease …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer
December 19, 2024ESR1, Menari Group, NICE, breast cancer, drug
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
December 16, 2024LEO Pharma, eczema
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain for Anzupgo® (delgocitinib) 20mg/g cream …
Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
December 13, 2024CPHI Milan, CPhI, networking
13 December 2024 – Amsterdam, the Netherlands –  CPHI Milan – the world’s largest pharma event – hosted last month …
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
December 12, 2024Corporate, Deep Science Ventures, General Inception, fibrosis, venture
12 December 2024 – London, UK, and Palo Alto, CA, US – Deep Science Ventures, a UK-based venture studio, and …
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
December 10, 2024Mounjaro, NICE, lilly, weight-loss
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute for Health and Care Excellence …
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
December 9, 2024Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …
Gemma Cathcart appointed managing partner at Langland
November 25, 2024Corporate, Langland
Langland, a medical life sciences company with focuses on areas surrounding Clinical Trial experience, Medical Strategy and Education, Public Relations …
Ceryx Medical Initiates First-In-Human Study of the Cysoniâ„¢ RSA Pacemaker
November 21, 2024Ceryx Medical, Devices, biotech
Ceryx’s Cysoni pacing technology is designed to provide superior therapeutic outcomes for Heart Failure patients by improving cardiac output using …
Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens
November 20, 2024AMR Week, Glox Therapeutics, antimicrobial resistance
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding …
Latest content
FibroFind appoints Lee Borthwick as CEO
